pCAR-19B cells用于急性淋巴细胞白血病的II 期研究｜NCT05334823

一分钟看懂

这是一项关于急性淋巴细胞白血病的II 期研究，登记的药物或干预包括pCAR-19B cells，当前状态为招募中。登记地点显示中国北京、重庆、深圳、武汉等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

pCAR-19B cells · II 期

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

Beijing Children's Hospital.Capital Medical University · 北京
Beijing GoBroad Boren Hospital · 北京
Children's Hospital of Chongqing Medical University · 重庆
Shenzhen Children's Hospital · 深圳
Pediatric Hematology department of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology · 武汉
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology · 武汉
Xiehe Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology · 武汉
The Second Xiangya Hospital, Central South University · 长沙
Affiliated Drum Tower Hospital, Medical School of Nanjing University · 南京
Jiangsu Province Hospital · 南京
Children's Hospital Of Soochow University · 苏州
The First Affiliated Hospital of Nanchang University · 南昌
West China Second University Hospital,Sichuan University · 成都
Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences · 天津
Children's Hospital, Zhejiang University School of Medicine · 杭州
The First Affiliated Hospital of Zhengzhou University · 河南省

1. The patient himself or his guardian agrees to participate in this clinical trial and signs the Informed Consent Form (ICF), indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the research;
2. Diagnosed with B-ALL，and meet one of the following conditions:
1. Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy;
2. Relapsed B-ALL: patients with early relapse (\<12 months) after complete remission;or late relapse (≥12 months) after complete remission, and relapsed patients who have not achieved complete remission after standard treatment or have poor response to early
3. For Ph+ALL patients, patients who have not achieved complete remission after receiving at least two Tyrosine kinase inhibitors (TKI) treatments or have relapsed after complete remission (except those who cannot tolerate TKI treatment or have contraindicatio
3. The malignant cells in the bone marrow were confirmed to express CD19 by flow cytometry;
4. Bone marrow morphology at the time of screening indicated that blasts≥ 5%;
5. Eastern Cooperative Oncology Group (ECOG) 0-1 points ;

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT05334823；登记信息更新于 2026-09-15。